Delivery Order SPE2DB24D2011-SPE2DB25FBRRA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,219.60 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor headquartered in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,178.96 delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count units) under a firm fixed price contract with a completion date of July 22, 2025. This non-set-aside award was competitively awarded and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract action under AmerisourceBergen's larger federal pharmaceutical supply arrangement with DLA....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of XCOPRI 50 MG tablets (30-count packages) valued at $7,622.85. This firm fixed-price delivery order represents a non-competitive award and carries an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,768.44 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,964.26 to AmerisourceBergen Drug Corp for 30 tablets of XCOPRI 100 mg on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price, competitively awarded contract is not associated with a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, served as the prime contractor for this pharmaceutical delivery. The order represents a relatively...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.44 for XCOPRI 150 mg tablets (30-count units) with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a $1,497.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $4,689.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count packaging) with a completion date of July 30, 2025. This non-set-aside competitive award was issued on July 29, 2025, with performance conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was selected...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count packaging) under a firm fixed-price contract valued at $1,768.44, with an ultimate completion date of August 20, 2025. This non-set-aside, competitively awarded delivery order was issued on August 19, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $2,432.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XCOPRI 150 mg tablets (30-count units) with a completion date of August 4, 2025. This non-set-aside contract represents a competitively awarded pharmaceutical supply transaction executed on August 1, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRRADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count) valued at $1,842.99 under a firm fixed price contract type. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying a comprehensive range of pharmaceutical products, medical devices, and healthcare commodities. The company's extensive contract portfolio with the Defense Logistics Agency demonstrates its capability to fulfill diverse federal medical procurement requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/25/25 |